These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8313363)

  • 1. T-cells for tumor therapy can be obtained from antigen-loaded sponge implants.
    Chen W; Reese VA; Cheever MA
    Cancer Res; 1994 Feb; 54(4):1065-70. PubMed ID: 8313363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
    Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
    J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
    Chen W; Reese VA; Cheever MA
    J Immunol; 1990 May; 144(10):3659-66. PubMed ID: 2332628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity.
    Zangemeister-Wittke U; Kyewski B; Schirrmacher V
    J Immunol; 1989 Jul; 143(1):379-85. PubMed ID: 2499633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
    J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo mechanisms of alloreactivity. I. Frequency of donor-reactive cytotoxic T lymphocytes in sponge matrix allografts.
    Orosz CG; Zinn NE; Sirinek L; Ferguson RM
    Transplantation; 1986 Jan; 41(1):75-83. PubMed ID: 2934878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
    Chen W; Cheever MA
    J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
    Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
    Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z; Fan H; Wu Y; Chen B
    Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.